KURA
Kura Oncology
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
KURA Profile
Kura Oncology, Inc.
A clinical-stage biopharmaceutical company that develops therapeutics for the treatment of solid tumors and blood cancers
12730 High Bluff Drive, Suite 400, San Diego, CA 92130
--
Kura Oncology, Inc., was originally incorporated in Delaware in November 2007. They are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine to treat cancer. Their pipeline consists of small molecule product candidates targeting cancer signaling pathways where there are strong scientific and clinical reasons to improve outcomes, which they intend to combine with molecular or cellular diagnosis to identify patients most likely to respond to treatment. They are conducting clinical trials on three product candidates: ciftominib, tipifarnib and KO-2806.